CagriSema (cagrilintide + semaglutide)
Combination therapy. NDA filed Dec 18, 2025 (REDEFINE-1/-2 pivotal trials); FDA decision anticipated late 2026 per Novo Nordisk, no confirmed PDUFA date. NOT YET APPROVED as of 2026-07-08 - some low-quality sites have falsely implied approval already happened; verified against Novo Nordisk's own investor announcement before publishing this note. REDEFINE-4 (Feb 23, 2026) missed its noninferiority endpoint vs tirzepatide 15mg at 84 weeks (23% CagriSema vs tirzepatide, did not meet noninferiority margin) - a real efficacy caveat. Manufactured by Novo Nordisk. FDA-approved status: pending.
Not yet FDA-approved - not available for purchase
CagriSema has not been approved by the FDA and cannot be bought at any pharmacy, manufacturer program, or telehealth service. Every price shown on this page is a pre-launch estimate, not a confirmed or purchasable price - Novo Nordisk has not announced pricing. For the current regulatory status and timeline, see the CagriSema FDA approval timeline.
CagriSema pricing across every channel
Manufacturer direct prices (LillyDirect, NovoCare) are usually cheapest. Updated May 2026.
| Drug | Insurance | Mfr direct | Telehealth (brand) | Telehealth (compd) | Cash retail | Get it |
|---|---|---|---|---|---|---|
| CagriSema 20.4% weight loss | $88 | $599 | - | - | $1,499 | - |
CagriSema cost in 2026 (estimated)
CagriSema is not yet approved or sold. The figures below are pre-launch estimates for context only, not prices you can pay today.
| Payment channel | Monthly | 12 months |
|---|---|---|
| Covered by insurance ($25–150 copay) | $88 | $1,056 |
| Manufacturer self-pay (LillyDirect / NovoCare) | $599 | $7,188 |
| Telehealth: brand name (Hims, Ro, Found) | Not available | - |
| Telehealth: compounded (limited post-FDA crackdown) | Not available | - |
| Cash retail (full list price) | $1,499 | $17,988 |
Dosing
Weekly subcutaneous injection. Combines cagrilintide (amylin analog) with semaglutide.
✓ Pros
- Highest efficacy of any pending GLP-1 (20.4% in REDEFINE-1)
- Dual mechanism (amylin + GLP-1) targets satiety differently
- Once-weekly injection like Wegovy
✗ Cons
- Pending FDA approval (expected 2026)
- Combination therapy may carry premium pricing
- Limited long-term real-world data
Common side effects
Most-reported in REDEFINE-1. Side effects are typically worst during dose escalation and improve over time.
Related cost guides
- → GLP-1 Savings Cards Compared - manufacturer copay programs for CagriSema and others
- → GLP-1 Prior Authorization Guide - what insurers want for CagriSema and how to win an appeal
- → Cheapest GLP-1 Finder - all 8 drugs ranked by cost-per-pound-lost
Compare CagriSema to other GLP-1s
CagriSema coverage by major insurer
Coverage stance and per-carrier details for CagriSema. Each link goes to the full prior-auth requirements, cost table, and appeal playbook for that carrier.